Twining Biotech, which was listed on the GEM in December 2022, is an enterprise engaged in the R&D and industrialization of biological fermentation technology, with a leading scale, complete product types and advanced production technology in the field of antibiotic intermediates in China and the world. Up to now, the company has 68 patents, including 31 invention patentsIn addition, it has more than 30 key core technologies such as fermentation technology and enzyme reaction technology with independent intellectual property rights, and is undertaking or participating in 11 major national, provincial and ministerial science and technology projects.
It is reported that the 500 cubic meter biological fermentation tank creatively used by Twining Biotechnology has solved the bottleneck problems of the design and construction of the super-large fermentation tank, the supply of dissolved oxygen in the fermentation liquid, the aseptic control, the nutrient transfer and related supporting facilities, and greatly improved the output and efficiency of a single batch, and the large-scale benefits are obvious. According to public information, the market share of the three main products of Twining Biologics, erythromycin thiocyanate, penicillin intermediates and cephalosporin intermediates has reached the leading position in the industry. For example, in the erythromycin thiocyanate market, the company's market share is more than 40%;In the penicillin market segment, the market share of 6-APA produced by the company ranks second among domestic enterprises.
One year after its listing, the comprehensive strength of Twining Biotech has been significantly improved. Major economic indicators such as operating income, net profit, total assets, and net assets all maintained double-digit growth, and the quality and efficiency of operations continued to improve. In the first three quarters of 2023, a total of 358.1 billion yuan, a year-on-year increase of 2183%；Net profit attributable to shareholders of listed companies64 billion yuan, a year-on-year increase of 9265%；Net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses63.9 billion yuan, a year-on-year increase of 7252%。On the whole, the overall performance in the first three quarters of 2023 is stable and improving, and the performance in the fourth quarter is promising.